November 13, 2026 · Journal of the American Society of Nephrology : JASN · DOI: 10.1681/ASN.0000001296

Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN.

Listen to this summary

This open-label extension of the VALIANT phase 3 trial asked whether the proteinuria reduction and kidney function stability seen with pegcetacoplan (a C3/C3b inhibitor) at 26 weeks persist through 52 weeks in patients with C3 glomerulopathy or primary immune-complex MPGN. Participants who received pegcetacoplan throughout maintained about a 67% reduction in proteinuria at week 52 with stable eGFR (-3.7 mL/min/1.73 m² change, not statistically significant), while those switched from placebo showed proteinuria reduction and eGFR stabilization after starting treatment. No new safety signals, encapsulated meningococcal infections, deaths, or allograft losses were reported, supporting sustained one-year benefit and an acceptable safety profile.

Carla M Nester, Andrew S Bomback, Gema Ariceta, Yahsou Delmas, Bradley P Dixon, Daniel P Gale, Larry A Greenbaum, Seung Hyeok Han, Nicole Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C Pickering, Giuseppe Remuzzi, Nicole C A J Van De Kar, Marina Vivarelli, Patrick D Walker, Dean Wallace, Daniel Zecher, Moglie Le Quintrec, Yael Borovitz, Nabil Melhem, Eli Khankin, Zhongshen Wang, Elena Surova, Johan Szamosi, Fadi Fakhouri

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play